There’s a small stack of potential teasers just sitting and waiting for the attention of the Thinkolator, but your friendly neighborhood Gumshoe is but a humble servant to the masses of the assembled Gumshoe faithful … so when I start getting hundreds of questions about one specific teaser, that moves to the top of the […]
Articles
- Most Relevant
- Most Recent
Saving Jack Kerouac[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. Enjoy!] His tidily rhyming names perhaps destined him for fame. While Jack Kerouac’s work and popularity were before my time, his cultural and literary restlessness assure him […]
If you ever want a dose of optimism, just read through (or listen to) any of the ads for Breakthrough Technology Alert — Patrick Cox will have you swelling with rosy thoughts about a future without disease or hardship, with a nice dose of 1,000,000% returns thrown in … that, after all, is the raison […]
Today we look, for a change, at a UK company — this teaser comes in from the folks at Fleet Street Publications (the British partner of our favorite newsletter megalopolis, Agora), in an ad for a letter called Dr. Mike Tubbs’ Research Investments. The letter appears to focus on breakout technology and biotech stocks, with […]
That’s right, the end of obesity. That’s what’s being touted by the new letter that as far as I can tell was just launched moments ago by Agora, which they’re calling FDA Trader and for which they apparently hired away Paul Mampilly from the Palm Beach Letter (OK, they didn’t really “hire him away” — […]
“How to get this $35,000/gram miracle cure for just $0.65” — that’s the subject line of the latest teaser ad we’re reviewing … how can you resist? The folks at Angel Publishing appear to be spinning off some of their newsletters, with Nick Hodge headlining, into a new little entity called the Outsider Club — […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
[Ed. Note: Dr. KSS writes about biotech stocks for the Irregulars. We have not reviewed or approved his topics or opinions, and he has agreed to our trade restrictions. Enjoy!] Twenty years ago, I was living life on an extreme slant as a medicine resident. My routine was a rut of working 36 hours, having […]
Those who are Irregulars know that I own shares of Ligand (LGND) and suggested it last summer in the mid-$30s, and have nibbled personally on the way up. My reasons for liking Ligand are basically two: They have a royalty-driven business model that provides potential upside with low capital needs; and they have a focus […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
My previous posting on Alzheimer’s focused on ways to avoid the most dire consequences of the disease in the absence of proven pharmaceutical interventions. The common assumption about disease management is that treatment begins when we develop symptoms. Then we go to the doctor, who most likely prescribes a course of treatment which probably includes […]
If the answer to those two questions should turn out to be an unequivocal “Yes!” that would definitely be cause for champagne and fireworks. Sorry to say that for now, at least, we have to put the champagne and fireworks on hold. But, who knows, might there be something – a few snippets […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions.] Tekmira (TKMR) shares have surged in response to announced use of its anti-Ebola RNAi therapeutic. Despite this, share action has occurred in […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!] In June 1962, women working in the dressmaking arm of a certain American textile factory were overcome with fear. Rumors began […]
[Ed note: Following is another installment from our favorite medical scribe, “Doc Gumshoe” (no, he’s not a doctor). We feature Michael’s commentary every couple weeks or so, and his thoughts and words are his own. “Doc” doesn’t pick stocks, but FDA decisions are a huge driver of investment success for pharmaceutical and biotech companies and […]
[ed. note: We feature the writings of Doc Gumshoe, our favorite medical scribe, every few weeks here at Stock Gumshoe. He is not a doctor, but we value his insight, research, contrariness and skepticism … and, most importantly, his ability to explain complex health issues for our readers. You can see all of Michael’s previous […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. His bio, past articles, and most recent comments can be seen here. Enjoy!] OUT of the night that covers me, Black as the Pit from pole to pole, I thank […]
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
I decided to add the year to my title in the event that this thing goes on for another full year, and I have to do an update in May 2021. I pray fervently that such an eventuality will not come to pass, but it’s certainly possible. Having said that, your obedient servant […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
[regular readers: this originally appeared last week and I’m just correcting some bad coding, sorry for any confusion] Can you really buy McDonald’s or Coca Cola for “pennies a share?” Leaving aside the fact that “pennies a share” means nothing, of course (with enough pennies, you could easily pick up some of Steve Sjuggerud’s favorite […]
I’ve had dozens of readers send this one along, most with a long line of question marks. The teaser has been around for a while (a couple years, as far as I can tell), but it continues to spark interest — especially with the dollar at ridiculous lows, inflation fears bubbling, and gold near $1,000 […]
Newsletters are notorious for re-using the same ad copy for years and years and years, and the Motley Fool is no different — when they get a marketing pitch that really works, they keep trotting it out again, and again, and again. I’ve mentioned this before, particularly with their “Next Berkshire Hathaway” pick that gets […]
Ah, another one from the Motley Fool! Like mother’s milk, it nourishes the Gumshoe so to pore through a ponderous Fool tome in search of clues to great stocks. Today, we’re blessed with a teaser letter for the Hidden Gems newsletter, with the letter coming from Bill Mann, who runs that newsletter in partnership with […]
OK, so leaving aside the fact that if you ever see a subject line like that in your email, you’re probably better off just deleting it, let’s take a little Gumshoe gander at the latest campaign from Toby Smith’s ChangeWave MicroCap newsletter. For those who don’t know him — and how you could avoid his […]
This here one is an oldie but a goodie — it’s one that I sniffed out back in April, when but a few courageous souls were following the Gumshoe’s exploits. Now that readership here has exploded tenfold or more, and this teaser ad, virtually word for word, has recently started making the rounds again, I […]
This one is from Chris DeHaemer at Taipan’s Red Zone profits, and it looks like it circulated pretty heavily on Friday and over the weekend. It’s for a company that uses momentum, in Dehaemer’s description, to store electrical energy, and essentially runs a big “momentum battery” that they use to buy up electricity at low […]
“Is it really possible to safely make $5,500 or more, in cash, in the next 24 hours?” That’s how they open this teaser for a new investment newsletter from Stansberry and Associates, called Jeff Clark’s Advanced Income. And just as an aside, duh, of course you can safely make $5,500 or more in 24 hours […]
If you want to get my goat, just start your teaser, “If you could own but one stock for the rest of your life, this would be it!” Come on people, something a little more original, please! Well, this fella is selling his service by essentially promising that this stock will turn you into a […]
I’m finding that sleuthing out stock picks is a healthy way to indulge in my stock market addiction on days like this, when I would otherwise be throwing money at what look to me like serious bargains, only to watch them fall a further 10 or 20% in the minutes following my purchase. So in […]
This is one I’m surprised I never got around to doing before — but I just had it sent to me again, and I know I’ve been seeing it fairly consistently since mid-May or so, so I might as well give it a quick writeup here. It was actually teased in the same ad as […]
Streetsifter strikes again — he sent in this solution for an email that just started circulating, and he sent it in before I had even gotten around to reading the email. He even wrote it up nicely, so most of what follows is just a minor edit of his words (I agree he’s clearly got […]
This ad comes to us from Andrew Mickey at Breakaway Investor, who we’ve heard from a few times before. The solution was suggested by a few readers, the first of whom was Randy Last-name-withheld-to protect-the-innocent, and one of them, one of the Stock Gumshoe Irregulars who wishes to remain anonymous (we’ll call him Streetsifter … […]
This piece deciphered the original “A.O.P.” teaser form 2007, the ad was revised and is now running again in 2012, we looked at the new version here. This one on the so-called American Oil Pension (A.O.P) has been making the rounds quite a bit lately, with lots of different variations over the past couple weeks […]
Well, I’ve now been sleuthing out these companies publicly, and tracking the performance of these advertising emails, for long enough to take a little look back and see if anything interesting has happened to these firms. The most widely hyped pick of the last week, for Porter Stansberry’s London natural resources bank, is probably too […]
Hi folks — this is a submission from a reader that I haven’t yet looked at, so you can follow up for yourselves. Don’t want to delay it while I try to find time, so have at it: The email ad in question is for the Venture Insider, and you may have seen this one […]
Rob Fannon and Dr. George Huang are analysts for a newsletter called The Medical Investor, and their publisher, George Rayburn, has a deal for you … sign up for a subscription, and you’ll get their new report, “The Most Profitable New Medical Device Investment in the World Right Now.” Or of course, since you’re a […]
This one was recently forwarded by a reader, with a tip as to the company he thought it was (he was right, too). And this is actually a company I owned a few years ago around their IPO, so this is also a nice bitter reminder that I shouldn’t have sold it. The ad is […]
This one is the $3.50 Coal Bed Methane (CBM) company that many of you have been asking about — it’s been teased several times recently by Mike Schaefer and the Pure Energy Report, which will run you about $495 for a year. Or … if you just want to know about this company … you […]
A reader sent this one in recently, and it’s a very short term bet so I’ll type my response up more quickly than usual: Here’s the deal: The Jump Start Package from Volume Spike Alert, whatever that is, wants you to subscribe … and in return, they’ll tell you about the company that has developed […]